Disability

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

6 months ago

Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than…

6 months ago

South Dakota Partners with Trualta to Support Family Caregivers

All caregivers in the state can access free resources at home PIERRE, S.D., June 27, 2024 /PRNewswire/ --The South Dakota…

6 months ago

Neuro20 Sparks Hope for Long COVID Recovery

White Paper discussing patient improvements and potential mechanisms for patients with Long COVID.TAMPA, FL / ACCESSWIRE / June 27, 2024…

6 months ago

Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

The device is intended for initial treatment in the acute settingSARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc.…

6 months ago

Lifeward Unveils Newest Addition to Its AlterG Anti-Gravity Product Line – Introducing AlterG NEO

Elevate your practice and revolutionize patient care with the all-new user-friendly design and the same patented DAP technology for precise…

6 months ago

Linus Health Introduces Person-Centered Approach to Establish Clinically Meaningful Benefits and Personalized Brain Health Care

Scalable, systematic and automated process captures and monitors metrics based on patients' treatment priorities for managing Alzheimer's disease and related dementias…

6 months ago

NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage

New molecule demonstrates efficacy in a challenging SCI modelExpanding pipeline into new indications of ischemic stroke and ALSVancouver, British Columbia--(Newsfile…

6 months ago

BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024

SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who…

6 months ago

Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis

OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV)…

6 months ago